公开(公告)号：US20160354410A1

公开(公告)日：2016-12-08

申请号：US15242666

申请日：2016-08-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Assaf LASK ,  Eran OPHIR ,  Noga OR-GEVA ,  Adva COHEN ,  Ran AFIK ,  Esther BACHAR-LUSTIG ,  Yaki EIDELSTEIN

IPC: A61K35/17 ,  A61K35/28 ,  C12N5/0783 ,  A61K45/06

CPC classification number: A61K35/17 ,  A61K31/517 ,  A61K35/28 ,  A61K39/001 ,  A61K45/06 ,  A61K2035/124 ,  A61K2039/5158 ,  C12N5/0602 ,  C12N5/0636 ,  C12N5/0637 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  A61K2300/00

Abstract: A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (GVHD) inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject.

公开(公告)号：US20170304412A1

公开(公告)日：2017-10-26

申请号：US15636683

申请日：2017-06-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit SAGI ,  Eitan WONG ,  Ran AFIK

IPC: A61K38/48 ,  C12N9/64

CPC classification number: A61K38/4886 ,  C12N9/6489 ,  C12Y304/24086 ,  Y02A50/473

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

公开(公告)号：US20230024587A1

公开(公告)日：2023-01-26

申请号：US17735146

申请日：2022-05-03

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Yaki EIDELSTEIN ,  Eran OPHIR ,  Assaf LASK ,  Ran AFIK ,  Noga OR-GEVA ,  Esther BACHAR-LUSTIG

IPC: A61K35/17 ,  A61K39/00 ,  C12N5/0783 ,  A61K35/22 ,  A61K35/26 ,  A61K35/28 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42

Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.

公开(公告)号：US20210162025A1

公开(公告)日：2021-06-03

申请号：US17166060

申请日：2021-02-03

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit SAGI ,  Eitan WONG ,  Ran AFIK

IPC: A61K38/48 ,  C12N9/64

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

公开(公告)号：US20180193384A1

公开(公告)日：2018-07-12

申请号：US15825275

申请日：2017-11-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Yaki EIDELSTEIN ,  Eran OPHIR ,  Assaf LASK ,  Ran AFIK ,  Noga OR-GEVA ,  Esther BACHAR-LUSTIG

IPC: A61K35/17 ,  A61K39/00 ,  A61K35/26 ,  A61K35/28 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  C12N5/0783 ,  A61K35/22 ,  A61K35/42 ,  A61K35/407 ,  A61K35/12

CPC classification number: A61K35/17 ,  A61K35/22 ,  A61K35/26 ,  A61K35/28 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K39/001 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/5158 ,  C12N5/0636 ,  C12N5/0637 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2502/1121

Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.